Published in J Exp Med on February 01, 1994
Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med (1996) 6.34
Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med (1995) 2.83
Cytokines in asthma. Thorax (1999) 2.64
Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. J Clin Invest (1997) 1.73
Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol (1996) 1.69
Intragranular vesiculotubular compartments are involved in piecemeal degranulation by activated human eosinophils. Traffic (2005) 1.56
Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res (2001) 1.38
Eosinophils in innate immunity: an evolving story. Cell Tissue Res (2010) 1.34
Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by interleukin 5: the role of specific adhesion molecules and phosphatidylinositol 3-kinase. J Exp Med (1998) 1.25
Genome-wide association study of antibody response to smallpox vaccine. Vaccine (2012) 1.23
Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes. J Exp Med (1999) 1.22
Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front Immunol (2014) 1.08
Spred-1 negatively regulates allergen-induced airway eosinophilia and hyperresponsiveness. J Exp Med (2005) 1.07
CD40 expression by human peripheral blood eosinophils. J Clin Invest (1996) 1.07
Stimulation of P2 purinergic receptors induces the release of eosinophil cationic protein and interleukin-8 from human eosinophils. Br J Pharmacol (2003) 1.06
Piecemeal degranulation in human eosinophils: a distinct secretion mechanism underlying inflammatory responses. Histol Histopathol (2010) 1.03
Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut (2005) 1.03
Activation of pulmonary dendritic cells and Th2-type inflammatory responses on instillation of engineered, environmental diesel emission source or ambient air pollutant particles in vivo. J Innate Immun (2010) 1.03
Exogenous farnesol interferes with the normal progression of cytokine expression during candidiasis in a mouse model. Infect Immun (2007) 1.02
Eosinophilia, parasite burden and lung damage in Toxocara canis infection in C57Bl/6 mice genetically deficient in IL-5. Immunology (1997) 0.99
Identification of interleukin-2 in human peripheral blood eosinophils. Immunology (1996) 0.99
A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunol Res (2014) 0.93
An interleukin 5 mutant distinguishes between two functional responses in human eosinophils. J Exp Med (1997) 0.88
Asthma: eosinophil disease, mast cell disease, or both? Allergy Asthma Clin Immunol (2008) 0.88
Perturbations in eosinophil homeostasis following treatment of lymphatic filariasis. Infect Immun (2000) 0.87
Mechanisms of eosinophil cytokine release. Mem Inst Oswaldo Cruz (2005) 0.86
Interleukin-4-promoted T helper 2 responses enhance Nippostrongylus brasiliensis-induced pulmonary pathology. Infect Immun (2008) 0.86
Rapidly boosted Plasma IL-5 induced by treatment of human Schistosomiasis haematobium is dependent on antigen dose, IgE and eosinophils. PLoS Negl Trop Dis (2013) 0.84
Eosinophil infiltration in post-transurethral resection prostatitis and cystitis with special reference to sequential changes of eosinophilia. Med Mol Morphol (2007) 0.83
Regulation of the interleukin-5 receptor alpha-subunit on peripheral blood eosinophils from healthy subjects. Clin Exp Immunol (2003) 0.83
Local and systemic pro-inflammatory and anti-inflammatory cytokine patterns in patients with chronic subdural hematoma: a prospective study. Inflamm Res (2012) 0.82
Expression of eotaxin in 3T3-L1 adipocytes and the effects of weight loss in high-fat diet induced obese mice. Nutr Res Pract (2011) 0.82
Humoral factors in ALS patients during disease progression. J Neuroinflammation (2015) 0.81
Eosinophilic cystitis in 3 dogs. Can Vet J (2000) 0.80
Essential role of phosphoinositide 3-kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation. Immunology (2008) 0.80
Chronic intestinal nematode infection induces Stat6-independent interleukin-5 production and causes eosinophilic inflammatory responses in mice. Immunology (2004) 0.79
Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study. Biomed Res Int (2015) 0.79
Pathogenic roles of eosinophils in guinea-pig contact sensitivity: regulation of dermal eosinophilia with remotely administered IL-5. Clin Exp Immunol (2000) 0.78
IL-4: an important cytokine in determining the fate of T cells. Biophys Rev (2014) 0.76
Expression and in vitro properties of guinea pig IL-5: comparison to human and murine orthologs. Mediators Inflamm (2000) 0.75
Th2 cells and cytokine networks in allergic inflammation of the lung. Mediators Inflamm (1995) 0.75
Role and Significance of Markers of Inflammation in the Asthmatic Disease. Open Access Maced J Med Sci (2015) 0.75
Parallel interleukin 5 synthesis by eosinophils in duodenal and skin lesions of a patient with dermatitis herpetiformis. Gut (1995) 0.75
A Mathematical Modeling Approach to Understanding the Effect of Anti-Interleukin Therapy on Eosinophils. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
Marked infiltration of eosinophils in necrotizing granulomas in the resected hepatic bed after cholecystectomy resulting from gallbladder cancer and metastatic liver cancer is associated with peculiar peripheral eosinophilia. Med Mol Morphol (2012) 0.75
Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med (1988) 4.60
Alkaline phosphatase and peroxidase for double immunoenzymatic labelling of cellular constituents. J Clin Pathol (1978) 3.36
Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology (1989) 2.98
Heterogeneity of human peripheral blood eosinophils: variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia. Int Arch Allergy Appl Immunol (1983) 2.17
Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med (1992) 1.88
IgA-induced eosinophil degranulation. J Immunol (1989) 1.82
Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest (1992) 1.81
Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils. J Exp Med (1991) 1.64
The role of the mucosal immune system in inflammatory bowel disease. Gastroenterol Clin North Am (1992) 1.59
Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic protein. Clin Exp Immunol (1988) 1.29
Release of granule proteins by eosinophils from allergic and nonallergic patients with eosinophilia on immunoglobulin-dependent activation. J Allergy Clin Immunol (1991) 1.15
Eosinophilic cystitis: the relationship of allergy in the urinary tract to eosinophilic cystitis and the pathophysiology of eosinophilia. J Urol (1974) 1.12
Human peripheral blood eosinophils produce and release interleukin-8 on stimulation with calcium ionophore. Eur J Immunol (1993) 1.11
Synthesis of interleukin-5 by activated eosinophils in patients with eosinophilic heart diseases. Blood (1993) 1.06
Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med (1999) 5.85
Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med (1992) 5.29
Human asymptomatic Ebola infection and strong inflammatory response. Lancet (2000) 5.20
Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology (1998) 5.02
Dysbiosis in inflammatory bowel disease. Gut (2004) 5.01
Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med (1993) 4.30
Isolation and structure of a human fibroblast interferon gene. Nature (1980) 4.16
Diaphragm function and alveolar hypoventilation. Q J Med (1976) 3.94
Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today (1991) 3.79
Evidence for tumour necrosis factor/cachectin production in cancer. Lancet (1987) 3.66
Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. Eur J Biochem (1986) 3.63
Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ (2000) 3.45
Molecular cloning of human interleukin 2 cDNA and its expression in E. coli. Nucleic Acids Res (1983) 3.44
An IgG-Fc receptor induced in cytomegalovirus-infected human fibroblasts. J Immunol (1976) 3.14
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med (1998) 3.13
Treatment of hepatic hydatid disease with mebedazole: preliminary results in four cases. Br Med J (1977) 3.10
Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expression. Nucleic Acids Res (1985) 3.09
Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med (1994) 2.96
Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol (2002) 2.79
Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism. Lancet (1999) 2.79
Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis (1998) 2.78
[Immunoenzymologic diagnosis of parasitic diseases. II. Quantitative immunoenzymology]. Lille Med (1976) 2.74
Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet (1992) 2.66
Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J Immunol (2001) 2.56
Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice. Infect Immun (1992) 2.50
Expression of human mucin genes in respiratory, digestive, and reproductive tracts ascertained by in situ hybridization. J Histochem Cytochem (1993) 2.46
Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol (1989) 2.36
Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol (1992) 2.33
TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme. Cell Mol Life Sci (2008) 2.23
Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum (1997) 2.21
Specific IgE antibodies in immune adherence of normal macrophages to Schistosoma mansoni schistosomules. Nature (1975) 2.19
Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol (1985) 2.18
Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition. J Biol Chem (1985) 2.18
Heterogeneity of human peripheral blood eosinophils: variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia. Int Arch Allergy Appl Immunol (1983) 2.17
Design and application of a cytokine-receptor-based interaction trap. Nat Cell Biol (2001) 2.17
A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet (2001) 2.13
Tumor necrosis factor causes bronchial hyperresponsiveness in rats. Am Rev Respir Dis (1992) 2.11
A new function for platelets: IgE-dependent killing of schistosomes. Nature (1983) 2.11
A simplified measurement of respiratory resistance by forced oscillation. J Appl Physiol (1970) 2.11
Interleukin-10 production during septicaemia. Lancet (1994) 2.05
Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology (1998) 2.04
Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol (1994) 2.04
Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med (1986) 2.03
A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell (2001) 2.02
Does one size fit all? Drug resistance and standard treatments: results of six tuberculosis programmes in former Soviet countries. Int J Tuberc Lung Dis (2005) 2.01
Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma. J Immunol (1986) 2.00
Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler (2007) 1.99
PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut (2006) 1.99
Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor. Eur J Biochem (1985) 1.99
Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. Eur J Immunol (2001) 1.96
High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature (1994) 1.95
Ligand binding was acquired during evolution of nuclear receptors. Proc Natl Acad Sci U S A (1997) 1.94
Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol (1995) 1.94
A scanning electron microscopic comparison of a high volume final flush with several irrigating solutions: Part 3. J Endod (1983) 1.94
Dysbiosis as a prerequisite for IBD. Gut (2004) 1.93
Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol (1994) 1.92
Human TNF mutants with selective activity on the p55 receptor. Nature (1993) 1.91
Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med (1999) 1.91
Purification and characterization of human interleukin-1 beta expressed in recombinant Escherichia coli. Eur J Biochem (1986) 1.89
Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med (1992) 1.88
Spontaneous secretion of interferon gamma and interleukin 4 by human intraepithelial and lamina propria gut lymphocytes. Gut (1998) 1.88
Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis (1996) 1.88
Role of IgE receptors in effector function of human eosinophils. J Immunol (1984) 1.87
Basophil activation tests for the diagnosis of food allergy in children. Clin Exp Allergy (2009) 1.83
Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. J Exp Med (2001) 1.79
Alloreactive cloned T cell lines. VI. Multiple lymphokine activities secreted by helper and cytolytic cloned T lymphocytes. J Immunol (1982) 1.78
Investigation of the increased incidence of gonorrhoea diagnosed in genitourinary medicine clinics in England, 1994-6. Sex Transm Infect (2000) 1.78
Adverse events in phase-I studies: a report in 1015 healthy volunteers. Eur J Clin Pharmacol (1998) 1.73
Interleukin-10 modulates susceptibility in experimental cerebral malaria. Immunology (1997) 1.73
Molecular crosstalk in host-parasite relationships: schistosome- and leech-host interactions. Parasitol Today (2000) 1.73
Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. Gastroenterology (1996) 1.73
Cloning and structure of the human immune interferon-gamma chromosomal gene. EMBO J (1982) 1.71
IgA antibodies against P30 as markers of congenital and acute toxoplasmosis. Lancet (1988) 1.70
Detection of blood chimerism after lung and heart-lung transplantation. The superiority of nested as compared with standard polymerase chain reaction amplification. Transplantation (1994) 1.69
Adolescents are not adults: developmental considerations in alcohol users. Alcohol Clin Exp Res (2000) 1.69
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology (1997) 1.69
Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology (1999) 1.68
Evidence for a unique human fibroblast interferon (IFN-beta 1) chromosomal gene, devoid of intervening sequences. Nucleic Acids Res (1981) 1.67
Serodiagnosis of toxoplasma infection using a purified parasite protein (P30). Clin Exp Immunol (1985) 1.64
Enterocolitis induced by autoimmune targeting of enteric glial cells: a possible mechanism in Crohn's disease? Proc Natl Acad Sci U S A (2001) 1.63
ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem (1996) 1.63
Fc receptors for IgE on human and rat eosinophils. J Immunol (1981) 1.63
Human cytokine responses to cardiac transplantation and coronary artery bypass grafting. J Thorac Cardiovasc Surg (1996) 1.63
Recombinant tumour necrosis factor inhibits malaria parasites in vivo but not in vitro. Clin Exp Immunol (1987) 1.62
Genetically related Escherichia coli strains associated with Crohn's disease. Gut (2001) 1.61
Evidence for IgE-dependent cytotoxicity by rat eosinophils. J Immunol (1981) 1.61